Preventing the Emergence of Temozolomide Resistance in Glioblastoma by PARP Inhibition
Date
2019-05-15
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Temozolomide (TMZ) is active against the subset of glioblastomas (GBMs) in which the O6-methylguanine DNA-methyltransferase (MGMT) gene is silenced by promoter methylation. Unfortunately, virtually all MGMT-methylated tumors acquire TMZ resistance and regrow in patients. In a preliminary study, we showed that inhibition of the DNA repair enzymes poly (ADP-ribose) polymerase-1 and -2 (collectively, ‘PARP’) reverses TMZ resistance in patient-derived GBM and oligodendroglioma cell lines (Chapter 3). While this suggests that PARP inhibitors may be useful for treating TMZ-resistant cases, we predict that greater clinical benefit can be derived from their use in TMZ-sensitive cases, where inhibition may prevent the emergence of TMZ-resistant cell populations. To test this hypothesis, we developed a model of acquired TMZ resistance in the MGMT- methylated GBM cell line U251N (Chapter 4). In this system, prolonged treatment of U251N with TMZ induces TMZ-resistant colonies of cells that frequently harbor mutations in and reduced expression of DNA mismatch repair genes, and less frequently re-express MGMT. In Chapter 5, we observed that co-treatment of the parent U251N line with TMZ and the PARP inhibitor ABT-888 prevents such resistant colonies from emerging. Moreover, co-treatment causes established resistant colonies to regress and may also enhance cell kill in TMZ-sensitive cellular subpopulations. For some colonies, however, sensitivity to PARP inhibition diminishes with increasing exposure to TMZ. Collectively, these observations suggest that PARP inhibitors may be optimally used early in newly-diagnosed, MGMT-methylated GBMs to prevent or delay progression to a TMZ-refractory disease state by targeting both TMZ-resistant and sensitive tumour subpopulations.
Description
Keywords
Citation
Yuan, A. (2019). Preventing the Emergence of Temozolomide Resistance in Glioblastoma by PARP Inhibition (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.